Also trades as: HUMAW (NASDAQ) · $vol 0M
HUMA NASDAQ
Humacyte, Inc.
1W: -6.4%
1M: -12.6%
3M: -32.3%
YTD: -46.5%
1Y: -70.4%
3Y: -82.4%
5Y: -95.8%
$0.52
+0.02 (+3.70%)
Weekly Expected Move ±4.7%
$0
$0
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
2 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (84)
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
State Street Corp Sells 2,201,392 Shares of Humacyte, Inc. $HUMA
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
BlackRock Inc. Takes $3.78 Million Position in Humacyte, Inc. $HUMA
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Humacyte (HUMA) Q2 2026 Earnings Call Transcript
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
Humacyte shares fall after Q2 revenue, EPS miss
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Here are the major earnings before the open Wednesday
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts
Amgen (AMGN) Q2 Earnings and Revenues Surpass Estimates
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
12 Health Care Stocks Moving In Thursday's Intraday Session
Why Is Humacyte Stock Falling Thursday?
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Biggest stock movers: ORCL, HUMA, and more
Humacyte prices $50M public offering of common stock at $1.05/share
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
12 Health Care Stocks Moving In Wednesday's After-Market Session
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
Humacyte (HUMA) Q1 2025 Earnings Transcript
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
Are Medical Stocks Lagging Agilon Health (AGL) This Year?
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
Humacyte (HUMA) Q1 2026 Earnings Transcript
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
Here are the major earnings before the open Wednesday
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte regains ex-U.S. rights to Symvess from Fresenius Medical Care
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Humacyte GAAP EPS of -$0.13 in-line, revenue of $0.47M misses by $0.88M
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
Earnings Scheduled For March 27, 2026
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Here are the major earnings before the open Friday
Humacyte Q4 2025 Earnings Preview
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It?
Humacyte secures $1.48M Symvess purchase commitment in Saudi Arabia
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?
Humacyte To Participate in Upcoming Investor Conferences
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results